● Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Soft Tissue Sarcoma (STS) · Sponsor: GI Innovation, Inc.

PhasePhase 1/Phase 2

Planned participants358

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Jay Kim · +82-2-404-2003 · Clinical-102@gi-innovation.com

Woosun Lee · +82-2-404-2003 · Clinical-102@gi-innovation.com

Always discuss trial participation with your own doctor first.

Locations (11)

Mayo Clinic in Arizona	Scottsdale, Arizona, United States	Recruiting
Mayo Clinic in Florida	Jacksonville, Florida, United States	Recruiting
Mayo Clinic in Minnesota	Rochester, Minnesota, United States	Recruiting
Memorial Sloan-Kettering Cancer Center	New York, New York, United States	Recruiting
Cleveland Clinic	Cleveland, Ohio, United States	Recruiting
Seoul National University Hospital	Seoul, Seoul, South Korea	Recruiting
St. Vincent's Hospital	Suwon, suwon, South Korea	Recruiting
Yonsei University Health System, Severance Hospital	Seoul, South Korea	Recruiting
Yonsei University Health System, Severance Hospital	Seoul, South Korea	Recruiting
Asan Medical Center	Seoul, South Korea	Recruiting
Samsung Medical Center	Seoul, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05824975